Management Team

John Chiplin BPharm PhD, MRPharmS Chief Executive Officer John Chiplin was appointed as Chief Executive Officer and Managing Director of Arana from January 2006. John’s experience at companies such as GlaxoSmithKline, Biosym Technologies and Geneformatics (founding CEO) has given him a broad range of international executive management experience in the Life Science industry. Immediately prior to joining Arana, John was head of the $300 million ITI Life Science fund in the UK.

Rob Crombie BA Mod Hons; PhD Vice President, Business Development – Technology Rob Crombie joined Arana in April 2004 and is responsible for marketing the company’s technology and products, establishing collaborative relationships and strategically in - and out-licensing technology assets. Rob comes from a senior business development post with ML Laboratories PLC, UK and has over 10 years of business development experience in the antibody sector. He had previously managed a technology development team in Cobra Therapeutics Ltd and was responsible, at ML Laboratories, for licensing an antibody production system to several top pharmaceutical and biotech companies. Rob’s PhD was in cancer genetics from the Beatson Institute, Scotland. He later gained a Howard Hughes post-doctoral fellowship to carry out research at Baylor College of Medicine, in Houston, Texas.

David Fuller MBBS, B.Pharm(Hons) Chief Medical Officer David Fuller joined Arana in October 2007. David is dually qualified in medicine and pharmacy with more than 20 years international experience in clinical development and commercialisation of new medicines. He has previously worked at Genzyme, Orphan Medical and CeNeS in a number of senior product development roles.

Niall Henderson BAcc, CA, ACA, AICD Chief Financial Officer and Company Secretary Niall Henderson joined Arana in December 2001. His career encompasses periods both in the accounting profession (with Deloitte in Glasgow and Sydney) and in commerce. He has over 25 years commercial accounting experience, most of which has been spent with the international TNT transport group. He held a number of senior financial positions both in Australia and in Europe both at a corporate and divisional level. He has been significantly involved in mergers and acquisitions and most recently held the position of Director and Chief Financial Officer of TNT Australia, the major express and logistics subsidiary of the TNT Post Group.

Cliff Holloway BPharm, PhD Vice President, Business Development - Products Cliff Holloway joined Arana in January 2006. With over 18 years business experience Cliff has been instrumental in the direction and expansion of the company’s operations in the US, Europe and Asia. Following his early career in clinical research with Eli Lilly and Novartis, Cliff has since held several business development positions in drug discovery platform, software technology and biopharmaceutical companies, including for Biosym Technologies, Molecular Simulations (Accelrys), Superscape and Pharmacopeia Drug Discovery Inc.

Phil Jennings BSc, BVSc, PhD, FTSE Chief Scientific Officer Phil Jennings joined Arana’s board in August 2004, having served as Arana’s Chief Scientific Officer since September 2001. He brings a depth of practical experience in patenting, intellectual property, biological and molecular science and its commercialisation, and in the resolution of commercial/licensing disputes. He is also the inventor on a number of important granted patents and patent applications including foundation patents for the biotechnology companies Gene Shears and Betabiotic. Prior to joining Arana, Phil was a Chief Research Scientist and Corporate Fellow of CSIRO.

Steffen Nock PhD President, US Operations Steffen Nock joined Arana in April 2005. He is the former President of Absalus Inc., having previously participated in the foundation of Zyomyx, a biotechnology company in Hayward, CA, exploiting antibody-based proteomics technologies. Prior to this, Steffen held scientific research positions at Stanford University, USA, and at the Max- Planck Institute in Germany. He was one of four founders of Absalus that was acquired by Arana in April, 2005, when he became President of the company’s US operation.